Black Diamond Therapeutics Reports Strong Phase 2 Results for Silevertinib in Frontline NSCLC Patients With EGFR Non-Classical Mutations
Key Highlights
- Positive Phase 2 trial results for silevertinib in 1L NSCLC with EGFR non-classical mutations (NCMs).
- Preliminary median progression-free survival (mPFS) of 15.2 months, notably exceeding historical benchmarks for currently available therapies.
- Robust central nervous system (CNS) activity with 86% CNS objective response rate (ORR); no new cases of de novo brain metastases reported.
- Overall response rate (ORR) of 60% and disease control rate (DCR) of 91% in a broad spectrum of EGFR-NCMs, including PACC mutations.
- Manageable and dose-dependent adverse event profile; no new safety signals observed.
- Company to discuss pivotal development plans with FDA later this year.
- Investor webcast scheduled for May 21, 2026 at 5:30 p.m. EDT.
- Presentation at the 2026 ASCO Annual Meeting on May 30, 2026.
Detailed Analysis
Black Diamond Therapeutics (Nasdaq: BDTX) announced highly encouraging results from its Phase 2 study evaluating silevertinib, an investigational fourth-generation tyrosine kinase inhibitor (TKI), as a frontline treatment for non-small cell lung cancer (NSCLC) patients harboring EGFR non-classical mutations (NCMs). These results, presented by Dr. Julia Rotow of Dana-Farber Cancer Institute, could represent a significant advancement for a patient subpopulation with historically poor outcomes and limited targeted treatment options.
Clinical Outcomes
- Patient Population: 43 treatment-naïve NSCLC patients enrolled at 200 mg once daily, representing a wide range of EGFR-NCMs, including compound and P-Loop and C-Helix Compression (PACC) mutations. Notably, 19 patients had brain metastases at baseline, with 7 having measurable CNS target lesions.
- Median Follow-up: 11.2 months.
- Durability of Response:
- Preliminary median PFS: 15.2 months (95% CI: 10.8; Not Evaluable)
- Median duration of response (DOR): Not reached (95% CI: 7.0; Not Evaluable)
- 53% of patients remain on therapy, with the longest duration at 23.5 months.
- CNS Activity:
- No patients developed de novo brain metastases over the follow-up period.
- CNS ORR (by RANO-BM): Maintained at 86%.
- Overall Response and Disease Control:
- ORR (by RECIST 1.1): 60%
- DCR: 91%
- Variant Allele Frequency (VAF) reduction observed in all evaluable patients across 25 unique EGFR-NCMs, including PACC.
Safety Profile
- No new safety signals observed.
- Rate of treatment-related adverse events (TRAEs) greater than Grade 3 reduced to 28% after dose reduction.
- Patients maintained or even deepened clinical responses after dose reduction.
- Data support a 150 mg once-daily dose for pivotal development going forward.
Upcoming Milestones & Shareholder-Relevant Information
- Pivotal Development: Black Diamond will meet with the FDA later in 2026 to discuss the pivotal development plan for silevertinib in this setting.
- ASCO Presentation: Full data will be presented at the 2026 ASCO Annual Meeting (Abstract 8519) by Dr. Julia Rotow on May 30, 2026, offering the oncology and investment communities further insights into silevertinib’s efficacy and safety.
- Investor Webcast: A live webcast for investors is scheduled for May 21, 2026 at 5:30 p.m. EDT, accessible on the company’s investor relations website.
About Silevertinib
Silevertinib is a fourth-generation, oral, covalent, brain-penetrant EGFR TKI designed to selectively target both classical and over 50 non-classical EGFR mutations in NSCLC, as well as key EGFR alterations seen in glioblastoma multiforme (GBM), including EGFRvIII. The drug is engineered to avoid paradoxical EGFR activation linked with reversible TKIs. Over 200 patients with EGFR-mutant NSCLC or EGFR-altered GBM have been treated to date.
In addition to the current trial in NSCLC, Black Diamond has initiated a randomized Phase 2 study of silevertinib in newly diagnosed EGFRvIII-positive GBM patients (NCT07326566) as of May 2026.
Implications for Investors & Shareholders
- Potential Practice-Changing Therapy: The significantly longer mPFS and high CNS activity position silevertinib as a potential new standard of care for NSCLC patients with EGFR-NCMs—an underserved segment with poor prognosis and limited options.
- Addressing Unmet Need: The data demonstrate activity across a broad spectrum of EGFR-NCMs, including challenging PACC mutations and patients with CNS involvement.
- Commercial Opportunity: If confirmed in pivotal studies and approved, silevertinib could tap into a substantial market in both NSCLC and GBM, driving future revenue and shareholder value.
- Regulatory Pathway: The company is actively planning discussions with the FDA for pivotal development, which could accelerate timelines to approval and commercialization.
- Price Sensitivity: These positive data, especially the mPFS, CNS activity, and safety profile, are likely to be viewed favorably by the market and could catalyze share price movement, especially as further data is released at ASCO and regulatory milestones are met.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. Please consult your financial advisor before making investment decisions. All forward-looking statements are subject to risks and uncertainties as outlined by Black Diamond Therapeutics in their public filings. Actual results may differ materially from those anticipated.
